The Therapeutic Effect of Thalidomide in Syringomyelia

Drug

General health

Online since 27 June 2024, updated 377 days ago

About this trial

This trial is enrolling 30 participants with refractory syringomyelia to test the effect of thalidomide. Thalidomide is a drug with anti-inflammatory and immune modifying properties. If included, participants will receive 50–200 mg of thalidomide once at nightime. Final testing of sensory and motor scores will be performed after 3 months.

Included participants

Gender

All

Age

18 - 80 years

Injury level

C1 - S5

Severity (AIS)?

Time since injury

All

Healthy volunteers

C1-S5

Additionally, participants must

NOT have a history of psychiatric diseases or seizures

NOT have transplanted organs

HAVE had surgical treatment of syringomyelia that was ineffective, or

What’s involved

Type

Drug

Details

- Participants will receive 50 – 200 mg of thalidomide once at nightime. - Thalidomide is a drug with anti-inflammatory and immunomodulatory properties. - Final testing of sensory and motor scores will be performed after 3 months.

Potential benefits

Main benefits

General health

Additional benefits

Arm/hand function

Pain

Sensory function

Standing/walking/mobility

Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

Wings for Life supports SCITrialsFinder

Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

Learn more

Back to results